[A22-41] Sacituzumab govitecan (breast cancer) - Addendum to Commission A21-154

Last updated 20.05.2022

Project no.:
A22-41

Commission:
Commission awarded on 13.04.2022 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Cancer

Indication:

Adult patients with unresectable or metastatic triple-negative breast cancer who have had two or more prior systemic therapies including at least one of them for advanced disease

Result of dossier assessment:

After addendum now indication of major added benefit

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2022-05-20 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form